Disease of older males.
The Philadelphia chromosome - BCR-ABL gene and it’s Tyrosine kinase protein – central to the pathogenesis.
Occurs in 3 phases
Imatinib has revolutionized the management
2. Definition, History & Epidemiology
Etiology and Pathogenesis
Clinical Features
Diagnosis
Course and special clinical situations
Differential Diagnosis
Risk assessment and Therapy
2
3. The World Health Organization Classification
System for Myeloproliferative Neoplasms
5. HISTORY
• In 1845, Bennett in Scotland and Virchow in Germany
described splenic enlargement, severe anemia, and
leukocytosis at autopsy
• Virchow proposed the term leukämie
• In 1878, Neumann proposed – marrow origin for leukemia –
myelogene (myelogenus)
• Nowell and Hungerford in 1960 identified the culprit gene at
the Perelman School of Medicine, Philadelphia
• Dr. Rowley identified the BCR-ABL translocation
• 1998 – Discovery of targeted TKI therapy
5
6. EPIDEMIOLOGY
• CML - 15 %of all cases of Leukemia
• US Incidence ~ 2 per lakh persons for men and 1.1 per lakh
persons for women
• Sparse Indian data - 0.8–2.2/lakh in men and 0.6–1.6/lakh in
women
• 50-70% of leukemias in Indian adults
• Male predominance (1.4:1)
• Average age at presentation – 50 yrs
• Incidence is least in Swedes
6
8. ETIOPATHOGENESIS
1. Environmental Leukemogens
• Very high doses of ionizing radiation*
• Chemical leukemogens - benzene and alkylating agents – are
not causative – increased incidence of AML
• No concordance of the disease between identical twins
• Several large studies – no links with smoking/diet/lifestyle
8
10. 2. The stem cell
Etiopathogenesis
10
CML Stem Cell
11. 2. The stem cell
• Acquisition of the BCR-ABL fusion gene in a single
multipotential hematopoietic cell CML stem cell
• Majority of these cells would be in G0 phase of the cell cycle
• These BCR-ABL stem cells favor differentiation over self-
renewal
• Ph chromosome is found on myeloid, monocytic, erythroid,
megakaryocytic, B-cells and sometimes T-cell proof that CML
derived from pluripotent stem cell
Etiopathogenesis
11
12. 2. The stem cell
• The CML stem cells have
no regulation of
proliferation
• Mediated by IL3 – GCSF
autocrine loop
• Immature granulocytes
>> mature granulocytes
Etiopathogenesis
12
13. 3. BCR-ABL protein (Tyrosine Kinase)
• BCR (breakpoint cluster region) gene on chromosome 22
fused to the ABL (Ableson leukemia virus) gene on
chromosome 9
• The fusion protein derived from the BCR-ABL gene is a
tyrosine kinase enzyme
• This particular protein is seen in small amounts normally*
• The ABL gene regulated tyrosine kinase
• BCR-ABL unregulated tyrosine kinase
Etiopathogenesis
13
14. 3. BCR-ABL (Tyrosine Kinase)
Etiopathogenesis
14
Altered adhesion
• No adhesion to
marrow stroma
• Reduced regulation
by marrow factors
Mitogenic
activation
• Activation of various
pathways
proliferation
Inhibition of
apoptosis
• Upregulation of Bcl-
2
• Uninhibited
proliferation
15. CLINICAL FEATURES
A. Symptoms
• At diagnosis – 70% symptomatic
• Easy fatigability
• Loss of sense of well-being
• Decreased tolerance to exertion
• Anorexia
• Abdominal discomfort
• Early satiety *
• Weight loss
• Excessive sweating
15
16. A. Symptoms
• Uncommon symptoms
• Night sweats
• Heat intolerance
• Gouty arthitis
• Left upper-quadrant and left shoulder pain*
• Urticaria
• Hyperleukocytic Syndrome —dyspnea, tachypnea, hypoxia,
lethargy, slurred speech
Clinical features
16
Mimics thyrotoxicosis
22. A. Laboratory studies
Bone Marrow studies
• Mitotic figures are increased
• Macrophages that mimic
Gaucher cells *
• Macrophages - engorged with
lipids - yield ceroid pigment -
imparting a granular and bluish
cast - sea-blue histiocytes
• Increased reticulin fibrosis
(Collagen type III) *
• Angiogenesis
Diagnosis
22
23. A. Laboratory studies
Other lab features :
• Neutrophil Alkaline Phosphatase reduced
• Serum B12 and transcobalamin increased (>10 ULN)
• Serum uric acid increased
• Lactate dehydrogenase increased
• Mean histamine levels increased
Diagnosis
23
24. B. Cytogenetics
• Study of the number and structure of chromosomes
• Samples from bone marrow myeloid cells
• The presence of the Philadelphia chromosome – shortened
chromosome 22*
• Cytogenetics cannot identify complex translocations
Diagnosis
24
26. C. Molecular Probes
i. FISH (Fluorescence In Situ Hybridization)
• Detect the BCR-ABL fusion gene on chromosome 22
• Qualitative
Diagnosis
26
27. C. Molecular Probes
ii. PCR (Polymerase Chain Reaction)
• Most sensitive test to identify and measure the BCR-ABL gene
(Quantitative)
• Can be performed on blood/marrow cells
• Amplifies the BCR-ABL derived abnormal mRNA
• One abnormal cell in one million cells can be detected
Diagnosis
27
28. COURSE OF THE DISEASE
• CML has 3 phases
28
I. Chronic Phase
• Most patients are asymptomatic
• Incidental leukocytosis/splenomegaly
• Bleeding and infectious complications are uncommon in the
chronic phase
29. II. Accelerated phase
defined by
• 10%–19% blasts in blood or bone marrow
• >20% basophils in blood or bone marrow
• Thrombocytosis, thrombocytopenia unrelated to therapy (<1
lakh or >10 lakh)
• New clonal chromosome abnormalities
• Anemia progresses and cause fatigue, loss of sense of well-
being
• Splenomegaly
• Ranges from 4-5 years before progressing
Course of the disease
29
30. III. Blast Crisis
defined by
• ≥20% blasts in blood or bone marrow
• Extramedullary blastic infiltration (Chloroma)
• Resembles acute leukemia
• 2/3 transform to myeloid blastic phase and 1/3 to lymphoid blastic
phase
• Infection and bleeding common
• Abdominal pain, bone pain
• Survival is 6-12 months (worse for myeloid phenotype)
Course of the disease
30
31. Special Clinical situations
Neutrophilic CML
• A rare variant of BCR-ABL–positive CML – leukocytosis
principally of mature neutrophils
• WBC count lower than that of classic CML
• Basophilia, myeloid immaturity in the blood, prominent
splenomegaly, or low leukocyte alkaline phosphatase scores –
all absent!
• Larger fusion protein than in classic CML
• Usually has an indolent course
• Now classified separately
Course of the disease
31
32. Special Clinical situations
Hyperleukocytosis (15% of cases)
• Intravascular flow-impeding effects of white cell counts greater
than 3,00,000/µL (upto 8 lakh)
• Impaired circulation of the lung, central nervous system,
special sensory organs, and penis
• resulting in some combination of
• Tachypnea, dyspnea, cyanosis,
• Dizziness, slurred speech, delirium, stupor,
• Visual blurring, diplopia, retinal vein distention, retinal
hemorrhages, papilledema,
• Tinnitus, impaired hearing,
• And priapism
Course of the disease
32
33. Special Clinical situations
Concurrence of Lymphoid Malignancies
1. CML - years after irradiation of non-Hodgkin or Hodgkin
lymphoma
2. Accelerated phase dedifferentiation of the CML clone
acute lymphoblastic transformation
3. Plasmacytic malignancies – positive association
4. Patients may present with Ph+ ALL, after chemotherapy-
induced remission, develop features of typical CML
Course of the disease
33
35. RISK ASSESSMENT
• 3 scores
1. Sokal score - 1984
2. Euro (Hasford) score – 1998
3. European Treatment and Outcome Study (EUTOS) –
2011
35
36. 1. Sokal score
• Age
• Spleen size
• Platelet count
• Peripheral blood blast percentage
• Was used in busulphan or hydroxyurea based therapy
• Low risk - <0.8
• Intermediate risk – 0.8 – 1.2
• High risk - >1.2
Risk assessment
36
37. 2. Hasford score
• Age
• Spleen size
• Platelets
• Blast cell percentage
• Eosinophil percentage
• Was used in interferon based therapy
• Low risk - <780
• Intermediate - 780-1480
• High risk >1480
Risk assessment
37
38. 3. The European Treatment and Outcome Study
(EUTOS) risk score
• Low risk - <87
• High risk - >87
• Also proposed a formula for predicting probability of
no CCyR at 18 months
• Presently used – ‘Imatinib era’
Risk assessment
38
(7 x basophil [%]) + (4 x spleen size)
40. 1. Initial therapy
• Allopurinol 300 mg/day orally with adequate hydration
Rasburicase 0.2 mg/kg i.v (one doses) for Hyperuricemia*
• Leukapheresis – helps reduce leucocyte burden, only in
conjunction with definitive therapy
• Hydroxyurea - Reversible suppression of hematopoiesis
1 to 6 g/day orally (titre based on counts)
• Anagrelide – to reduce the platelet burden
Treatment
40
41. 2. Tyrosine Kinase inhibitor therapy
Treatment
41
First generation Second generation
Imatinib
Dasatinib
Nilotinib
Bosutinib
Ponatinib
Bafetinib
42. 2. Tyrosine Kinase inhibitor therapy
Imatinib Mesylate
• Approved for use in Ph+ CML in 2001
• Preliminary studies showed a remarkable cytogenic
remission
• Hematological remission was seen in 95%
• Now the treatment of choice for CML
Treatment
42
48. 2. Tyrosine Kinase inhibitor therapy
Imatinib Mesylate
Treatment
48
National Comprehensive Cancer Network
49. 2. Tyrosine Kinase inhibitor therapy
Imatinib Mesylate
Treatment
49
European Leukemia Net
50. 2. Tyrosine Kinase inhibitor therapy
Imatinib Mesylate
Four mechanisms of resistance
(1) Gene amplification
(2) Mutations at the kinase site
(3) Enhanced expression of multidrug exporter proteins
(4) Alternative signaling pathways compensating imatinib-
sensitive mechanisms.
Treatment
50
51. 2. Tyrosine Kinase inhibitor therapy
2nd Generation TKI
1. Dasatinib
• Used in imatinib resistance or intolerance
• 325-fold more potent than imatinib
• 100 mg/day, administered in chronic phase CML
• Unlike imatinib, dasatinib penetrates the blood–brain barrier
• Cytopenia, followed by fluid retention, diarrhea, and skin rash
Treatment
51
52. 2. Tyrosine Kinase inhibitor therapy
2nd Generation TKI
2. Nilotinib
• Used in imatinib resistance or intolerance
• 30 times more potent than imatinib
• ATP-competitive inhibitor of BCR-ABL
• 400 mg every 12 hours
• Neutropenia, hyperbilirubinemia, hypophosphatemia, QT
interval prolongation
• Imatinib and nilotinib in combination may have additive or
synergistic effects
Treatment
52
53. 3. Interferon α
• IFNα was the initial therapy before TKI therapy
• Complete cytogenetic response – uncommon (13%)
• 50% responders – long term survival
• 3-5 million units/m2 five times per week
• Neurotoxicity, thrombocytopenia, fatigue, and liver
dysfunction dose limiting effects
• Single dose of 450 µg pegylated IFNα – comparable
• IFNα was combined with Cytarabine
• Some patients intolerant to a Imatinib may be treated
successfully with INFα
Treatment
53
54. 4. Chemotherapeutic Agents and other modalities
i. Cytarabine
• IFNα combined with cytarabine (20 mg/m2/day -10 days
per month better than IFN alone
• Replaced by TKI
ii. Busulfan
• Once the mainstay of treatment – now almost never used
• Use limited to the preparative regimen for allografting or
autografting
Treatment
54
55. 4. Chemotherapeutic Agents and other modalities
iii. Splenectomy*
• Delay the onset of the accelerated phase
• Enhance sensitivity to chemotherapy
• Prolong survival of patients
• But, does not prolong the chronic phase
iv. Radiotherapy
• Splenic irradiation - extreme splenomegaly with splenic
pain, perisplenitis
• may be useful for extramedullary tumors (bone/soft tissue)
Treatment
55
56. 4. Chemotherapeutic Agents and other modalities
v. Omacetaxine (formerly Homoharringtonine)
• Protein translation inhibitor
• Still in Phase 2 trials
• Showed promise in TKI intolerant/resistant cases
• 18% major cytogenetic response in TKI failed cases
vi. Experimental
• Lonafarnib and tipifarnib
• Berbamine
• Adaphostin
• Third-generation TKIs
Treatment
56
57. 5. Allogeneic Stem Cell Transplantation
• Allogeneic HSCT - complicated by mortality owing to the
procedure
(1) The patient
(2) The type of donor
(3) The preparative regimen (myeloablative or reduced-
intensity)
(4) Graft versus Host Disease
(5) Post-transplantation treatment
Treatment
57
58. 6. Treatment of accelerated/blast phases
• Goal achieve remission
• Else aim to reduce to chronic phase
• TKI – bridging therapy to permit allogenic SCT
• Dasatinib and nilotinib achieve better molecular remission in
accelerated phase
• Imatinib+mitoxantrone+etoposide
• Imatinib+cytarabine
• Ultimately – Stem cell transplant
Treatment
58
Blast crisis
59. 7. Treatment of CML in pregnancy
• Untreated CML placental insufficiency (leukostasis)
• Risk of teratogenicity with Imatinib
• IFN is safe – can be used
• Leukapheresis – 1st trimester
• Hydroxyurea – 2nd and 3rd trimester
• Restart TKI therapy soon after delivery
Treatment
59
60. 8. Treatment cessation
• Despite achieving deep and lasting remissions
• CML is not curable
• Patients with remissions - have residual CML cells (PCR)
• Evidence suggests - people who receive TKIs may remain in
remission for very long periods
• Research still underway
Treatment
60
62. CONCLUSION
• Disease of older males
• The Philadelphia chromosome BCR-ABL gene and it’s
Tyrosine kinase protein – central to the pathogenesis
• Occurs in 3 phases
• Most patients in the chronic phase - asymptomatic
62
63. CONCLUSION
• Imatinib has revolutionized the management of CML
• Long term survival is a reality now
• TKI therapy is still not curative
• 3rd generation TKI and newer drugs in the pipeline show
some promise at achieving a possible cure
63
Editor's Notes
CMML – monocytes >1000, BCR-ABL negative, pdgfra+
Bennett initially favored an extreme pyemia as the explanation, but Virchow argued against suppuration as a cause
TKI – Approved in 2001
<0.3% patients reported
<0.3% patients reported
very high doses of ionizing radiation – 3 major populations
Hiroshima Nagasaki 1945
British ankylo spond spine irradiation
uterine cervical carcinoma who received radiation therapy
BCR – breakpoint cluster region
ABL – Abelson Leukemia gene
Interferon-α reduces adhesion defects
BCL2 is an apoptosis inhibitor
vague, nonspecific, and gradual in onset (weeks to months)
*Attributable to splenic enlargement
*Splenic infarcts
Histamine
perivascular infiltrate of neutrophils in the dermis
fever and painful maculonodular violaceous lesions
trunk, arms, legs, and face
*Massive - and in almost all patients
Sternal tenderness – lower part – patient can detect
Elevated leukocyte count. Characteristic array of immature (myelocytes, metamyelocytes, band forms) and mature neutrophils.
Two basophils in the field. Absolute basophilia is a constant finding in CML
Hypercellular.
Replacement of fatty tissue (normally ~60% of marrow volume ) with hematopoietic cells.
Intense granulopoiesis and evident megakaryocytopoiesis.
Decreased erythropoiesis
Granulopoeisis – 10 to 30:1 (N 2-4 :1)
glucocerebrocidase overload due to high turnover of glucocerebrocide*
Collagen type III – correlates with spleen size and megakaryocytosis*
Angiogenetic marrow – reduces with treatment
Neutrophil alkaline phosphatase activity is low or absent (90%) - Activity increases with treatment (limited use)
B12 – immature cell leak
Uric acid – gout/uropathy
Histamine increase with basophil
90%
In normal cells, two red and two green signals indicate the location of the normal ABL and BCR genes, respectively.
In abnormal cells, the BCR-ABL fusion is visualized through the fusion of the red and green signals. It is frequently detected as a yellow fluorescence (noted by arrows).
European Society of Medical Oncology (ESMO) 15-29%
European Society of Medical Oncology (ESMO) >30%
vPlasmacytic - Multi myeloma, Waldenstroms etc
Myeloproliferative TC <3 lakh (in 90%)
1 - PV – High Hb - AQUAGENIC PRURITIS, ERYTHROMELALGIA
2- essential thrombocythemia have a platelet count greater than 450,000
3 - Myelofibrosis - teardrop poikilocytes and other severe red cell shape, size, and chromicity changes
JAK2 (PV>other MPD > CML)
4 - leukemoid reaction overt inflammatory disease
*applied at diagnosis before starting treatment
*applied at diagnosis before starting treatment
*applied at diagnosis before starting treatment
*applied at diagnosis before starting treatment
cell lysis* - Febuxostat – little evidence in CML
Other uses
MDS
ALL
GI stromal tumours
Hyper eosinophillic syndrome
Dermatofibrosarcoma protuberans
All four mechanisms are being targeted in clinical trials.
Bosutinib
Ponatinib (active against T315I)
Careful selection of the case is a must
Farnesyltransferase inhibitors
1 Patient – age and phase
2 Donor - monozygotic twins or hla-compatible allogeneic, related or unrelated
he T315I mutation results in an amino acid substitution at position 315 in BCR-ABL1, from a threonine (T) to an isoleucine (I)